[A randomized controlled clinical study of sparfloxacin versus ofloxacin in the treatment of bacterial infections].
To evaluate the efficacy and safety of sparfloxacin in the treatment of bacterial infections. A randomized controlled multi-centre clinical trial was conducted. Ofloxacin used as the control drug. A total of 212 patients entered the study, with 106 in the sparfloxacin group and the remaining 106 in the ofloxacin group. Both compounds were given by oral administration. The cure rate of sparfloxacin and ofloxacin was 74.5% and 69.8% respectively and the overall efficacy rate was 91.5% and 88.7% respectively. The bacterial clearance rate was 90.7% in the sparfloxacin group and 90.8% in the ofloxacin group. The adverse drug reaction rate of sparfloxacin and ofloxacin was 9.43% and 8.49% respectively. There was no statistical significant difference between the two groups for the above results. The results of in vitro activity of sparfloxacin as compared with other 5 antibacterial agents showed that sparfloxacin had good activity against many Gram-negative organisms and was similar to those of ofloxacin. The activity against Gram-positive organisms (MIC(90) <or= 0.25 mg/L) was generally higher than that of ofloxacin. Sparfloxacin is a highly effective and safe broad-spectrum antibacterial agent for the treatment of bacterial infections. It is also effective in the treatment of infections caused by Gram-positive organisms.